Axomadol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Axomadol
Axomadol structure.png
Systematic (IUPAC) name
(1R,3R,6R)-6-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-1,3-cyclohexanediol
Clinical data
Legal status
Identifiers
CAS Registry Number 187219-95-0
187219-99-4
ATC code None
PubChem CID: 10221318
ChemSpider 8396810
Chemical data
Formula C16H25NO3
Molecular mass 279.375 g/mol

Axomadol (INN, USAN) (code name EN3324) is a synthetic, centrally-acting opioid analgesic of the benzenoid class which was under investigation by Endo Pharmaceuticals in collaboration with Grünenthal for the treatment of chronic, moderate to severe lower back pain and arthrosis.[1][2] Development was halted after phase II clinical trials as it did not meet the pre-determined clinical endpoints.[3]

See also[edit]

References[edit]

  1. ^ Chadds Ford (2011-06-30). "Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11. 
  2. ^ US Abandoned 20100331424, Schiene K, Bloms-Funke P, Bothmer J, Lefeber C, "Use of Axomadol for Treatment of Arthrosis Pain", published 2010-12-30, assigned to Grünenthal GmbH 
  3. ^ Chadds Ford (2011-08-17). "Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.